Pharmaceuticals US

US Antiviral Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Antiviral Drugs Market Industry Trends and Forecast to 2034: Segmented by (Virus, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $23.55 Bn Placeholder estimate
Estimate 2025 $23.81 Bn 40.8% of the global market
Projected 2034 $26.27 Bn 10.3% Adds $2.46 Bn over 9 forecast years
CAGR 2025–2034 1.1% Faster than 2% of 180 Pharmaceuticals markets here
Key players 6 +1
  • US is 40.8% of the global market.
  • In North America, the largest is US (this report) at $23.81 Bn.
  • Fastest growing: Canada at 2.7% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.46 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Antiviral Drugs Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $23.55 Bn — —
2025 (base) $23.81 Bn +$259.0 Mn —
2026 (forecast) $24.07 Bn +$261.9 Mn +1.1%
2027 (forecast) $24.33 Bn +$264.7 Mn +2.2%
2028 (forecast) $24.60 Bn +$267.7 Mn +3.3%
2029 (forecast) $24.87 Bn +$270.6 Mn +4.5%
2030 (forecast) $25.14 Bn +$273.6 Mn +5.6%
2031 (forecast) $25.42 Bn +$276.6 Mn +6.8%
2032 (forecast) $25.70 Bn +$279.6 Mn +8%
2033 (forecast) $25.98 Bn +$282.7 Mn +9.1%
2034 (forecast) $26.27 Bn +$285.8 Mn +10.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Antiviral Drugs Market Analysis at a glance
Market size, 2025$23.81 Bn placeholder estimate
Forecast, 2034$26.27 Bn placeholder estimate
Growth (CAGR), 2025–20341.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsVirus, route and end user (see all)
Key playersGilead Sciences, Inc., GSK PLC, Merck & Co., Inc., Pfizer Inc., AbbVie Inc. and 1 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Antiviral Drugs Market Analysis Executive Summary

Antiviral drugs treat infections caused by viruses such as HIV, hepatitis, influenza, herpes and COVID-19.

Key segments of the antiviral Drugs market include virus (HIV, Hepatitis B and C and Influenza) and route (Oral, Injectable and Topical).

Bar chart: US Antiviral Drugs market size, 2024–2034, placeholder estimates. $23.55 Bn in 2024, $23.81 Bn in 2025 and $26.27 Bn in 2034, 1.1% CAGR.
US Antiviral Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Antiviral Drugs Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antiviral Drugs market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the antiviral Drugs market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antiviral Drugs market.

Competitive Landscape for Antiviral Drugs Market in US

The antiviral Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Antiviral Drugs Market in US

Antiviral Drugs in the US: rules and payment

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antiviral Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antiviral Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antiviral Drugs in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Antiviral Drugs market in the US?
Placeholder estimate: about $23.81 Bn in 2025, rising to about $26.27 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Antiviral Drugs market in the US growing?
Placeholder estimate: about 1.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Antiviral Drugs market report cover?
The report splits the market by virus (HIV, Hepatitis B and C, Influenza, Herpes and more), route (Oral, Injectable, Topical) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Antiviral Drugs market?
Key players include Gilead Sciences, Inc., GSK PLC, Merck & Co., Inc., Pfizer Inc., AbbVie Inc. and Roche.
What is driving the Antiviral Drugs market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antiviral Drugs market.
Who regulates Antiviral Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How much research is published on Antiviral Drugs?
PubMed lists 4,726 papers on Antiviral Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on infectious diseases and hiv

See the topic